Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours.
The incidence of neuroendocrine tumours (NETs) is increasing, but curative therapeutic options are limited because diagnosis is often delayed until the tumour has metastasized. Peptide receptor radionuclide therapy (PRRT) is among the most effective therapeutic options for metastatic NETs because of...
| Publicado en: | European Journal of Nuclear Medicine & Molecular Imaging Vol. 47; no. 4; pp. 907 - 922 |
|---|---|
| Autores principales: | , , |
| Formato: | Journal Article |
| Publicado: |
Springer Nature
Apr2020
|
| Acceso en línea: | Ver este registro en EBSCOhost |